| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Multiple myeloma is the second most common refractory hematological malignancy. Although mean survival is extended by development of new molecular target drugs made of small molecules or antibodies, drug-resistant myeloma cells emerge in most of the patients and result in subsequent relapse of cancer.
We have developed TRUE gene silencing as a gene expression suppression technology using sgRNA, and our final goal is to discover therapeutic sgRNAs to cure multiple myeloma. In this study, we found a candidate sgRNA drug that can change macrophages that support myeloma growth to those that attack myeloma cells, and demonstrated that this sgRNA drug can suppress tumor growth in a mouse model experiment.
|
